Hutchison China MediTech Limited Sponsored ADR Stock

$14.27

1.38% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

US44842L1035

Symbol

HCM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Hutchison China MediTech Limited Sponsored ADR Stock price

$14.27

-11.22 44.02% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.20 1.38%

ISIN

US44842L1035

Symbol

HCM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.49b
Enterprise Value	$1.78b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	2.88
P/S ratio (TTM) P/S ratio	4.03
P/B ratio (TTM) P/B ratio	3.36
Revenue growth (TTM) Revenue growth	-19.35%
Revenue (TTM) Revenue	$617.39m
EBIT (operating result TTM) EBIT	$-122.81m
Free Cash Flow (TTM) Free Cash Flow	$-85.17m
EPS (TTM) EPS	$-0.25
P/E forward	negative
P/S forward	3.73
EV/Sales forward	2.67
Short interest	0.50%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Hutchison China MediTech Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

13x Buy

100%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Hutchison China MediTech Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	617 617	19% 19% 100%
- Direct Costs	360 360	7% 7% 58%
Gross Profit	257 257	32% 32% 42%
- Selling and Administrative Expenses	113 113	4% 4% 18%
- Research and Development Expense	256 256	28% 28% 41%
EBITDA	-112 -112	13% 13% -18%
- Depreciation and Amortization	11 11	30% 30% 2%
EBIT (Operating Income) EBIT	-123 -123	15% 15% -20%
Net Profit	-43 -43	18% 18% -7%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Hutchison China MediTech Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

16 days ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA ® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limit...

Neutral

GlobeNewsWire

●

17 days ago

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China's National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the trea...

Neutral

PRNewsWire

●

25 days ago

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

SAN FRANCISCO, U.S. and SUZHOU, China , Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AI...

More Hutchison China MediTech Limited Sponsored ADR News

Company Profile

Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.

Head office	Cayman Islands
CEO	Wei Su
Employees	1,988
Founded	2000
Website	www.hutch-med.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now